Actavis announced it has received approval from the FDA on its Abbreviated New Drug Application (ANDA) for Telmisartan Immediate-Release Tablets, the generic version of Boehringer Ingelheim’s Micardis.

RELATED: Cardiovascular Disease Resource Center

Telmisartan is an angiotensin II receptor blocker indicated for the treatment of hypertension, to decrease blood pressure and cardiovascular risk reduction in patients unable to take ACE inhibitors. 

Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.

Telmisartan Immediate-Release Tablets will be available in 20mg, 40mg, and 80mg strengths. Actavis plans to launch the product immediately.

For more information call (800) 432-8534 or visit